Table 1.

Summary of previously reported cases of ocular adverse effects in relation to the same chemotherapeutic agents.

Author	Ocular surface adverse effect	Chemotherapeutic agent/etiology	Onset
Oh [13]	Autoimmunekeratitis	Atezolizumab/bladder cancer	Two months after initiating the treatment
Bitton et al [14]	Bilateralcicatrizing conjunctivitis Superficial punctate keratitis Inferior fornix shortening and tarsal conjunctival fibrosis	Atezolizumab/parotid adenocarcinoma	After 10 cycles
Aschauer et al [15]	Unilateral severe granulomatous conjunctival inflammation mimicking conjunctival metastasis	Atezolizumab/metastatic non-small-cell lung cancer	After 4 cycles
Venkat et al [6]	Bilateral superior limbic keratitis Posterior uveitis and macular edema	Atezolizumab/advanced squamous cell carcinoma of the lung.	Five months after initiating the treatment
Mito et al [17]	Bilateral anterior uveitis	Atezolizumab/non-small-cell lung cancer	Three weeks after the first cycle of atezolizumab
Biswas et al [20]	Opticneuropathy	Bevacizumab/cutaneous melanoma	Occurring 11 days after the first cycle of bevacizumab
Sherman et al [21]	Six cases of severe optic neuropathy	Bevacizumab/glioblastoma	3–18 months after initiating the treatment